Gregory Balani is a seasoned pharmaceutical business development executive, currently serving as VP at Mendra. A Doctor of Pharmacy from UCSF, he has a strong track record in corporate strategy, playing key roles in the acquisitions of Escient Pharmaceuticals by Incyte for $750M and Zogenix by UCB for $1. 9B.
His academic work includes publications on the cost-effectiveness of cancer treatments and ethical issues in microfinance, demonstrating a deep interest in the intersection of healthcare economics and social impact. He earned his Bachelor of Science from DePaul University.
Unique fact: He has been instrumental in two major pharmaceutical company acquisitions with a combined value of over $2. 6 billion.
Read the full overview →Behavioral traits and communication patterns that shape how this person evaluates opportunities, builds trust, and makes decisions in professional settings.
Dominance, influence, steadiness, and calculativeness scores with guidance on how this person prefers to communicate and decide.
Discover additional public profiles from our index.
Looking for someone else? Search here for anyone.